Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease
- PMID: 31612544
- PMCID: PMC9125340
- DOI: 10.1002/ajh.25656
Higher rates of bleeding and use of treatment products among young boys compared to girls with von Willebrand disease
Abstract
There are limited observational studies among children diagnosed with von Willebrand Disease (VWD). We analyzed differences in bleeding characteristics by sex and type of VWD using the largest reported surveillance database of children with VWD (n = 2712), ages 2 to 12 years old. We found that the mean ages of first bleed and diagnosis were lowest among children with type 3 VWD. It was even lower among boys than girls among all VWD types, with statistically significant difference among children with type 1 or type 3 VWD. Children with type 3 VWD also reported higher proportions of ever having a bleed compared to other VWD types, with statistically higher proportions of boys compared to girls reporting ever having a bleed with type 1 and type 2 VWD. A similar pattern was observed with the use of treatment product, showing higher usage among type 3 VWD, and among boys than girls with type 1 and type 2 VWD. While there were no differences in life quality or in well-being status by sex, children with type 3 VWD showed a greater need for mobility assistance compared to children with type 1 and type 2 VWD. In an adjusted analysis among children with type 1 VWD, boys showed a significant association of ever bleeding [hazard ratio 1.4; P-value <.001)] compared to girls. Understanding phenotypic bleeding characteristics, well-being status, treatment, and higher risk groups for bleeding among pre-adolescent children with VWD will aid physicians in efforts to educate families about bleeding symptoms.
© 2019 Wiley Periodicals, Inc.
Conflict of interest statement
CONFLICT OF INTEREST AND DISCLAIMER STATEMENT
The authors K.A., B.D., M.O., V.B., M.S., R.K., and S.O. report no actual or potential conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.
Comment in
-
Burden on parents of children with moderate or severe von Willebrand disease: The impact of clinical data.Haemophilia. 2023 Jan;29(1):390-393. doi: 10.1111/hae.14718. Epub 2022 Dec 16. Haemophilia. 2023. PMID: 36524543 No abstract available.
Similar articles
-
Baseline factor VIII plasma levels and age at first bleeding in patients with severe forms of von Willebrand disease.Haemophilia. 2016 Jul;22(4):564-9. doi: 10.1111/hae.12900. Epub 2016 Feb 4. Haemophilia. 2016. PMID: 26843468
-
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.J Thromb Haemost. 2020 Sep;18(9):2145-2154. doi: 10.1111/jth.14886. Epub 2020 Aug 25. J Thromb Haemost. 2020. PMID: 32379400
-
Von Willebrand Disease: Gaining a global perspective.Haemophilia. 2023 Jul;29(4):1104-1112. doi: 10.1111/hae.14804. Epub 2023 May 22. Haemophilia. 2023. PMID: 37216656
-
How I manage severe von Willebrand disease.Br J Haematol. 2019 Nov;187(4):418-430. doi: 10.1111/bjh.16186. Epub 2019 Sep 9. Br J Haematol. 2019. PMID: 31498884 Free PMC article. Review.
-
Clinical significance of slightly reduced von Willebrand factor activity.Pol Arch Intern Med. 2020 Mar 27;130(3):225-231. doi: 10.20452/pamw.15162. Epub 2020 Jan 28. Pol Arch Intern Med. 2020. PMID: 31990275 Review.
Cited by
-
Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241264541. doi: 10.1177/10760296241264541. Epub 2024 Jul 21. Clin Appl Thromb Hemost. 2024. PMID: 39033425 Free PMC article.
-
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research to advance the health of people with inherited bleeding disorders with the potential to menstruate.Expert Rev Hematol. 2023 Mar;16(sup1):71-86. doi: 10.1080/17474086.2023.2175660. Expert Rev Hematol. 2023. PMID: 36920864 Free PMC article.
-
Von Willebrand Disease Epidemiology, Burden of Illness and Management: A Systematic Review.J Blood Med. 2023 Mar 2;14:189-208. doi: 10.2147/JBM.S389241. eCollection 2023. J Blood Med. 2023. PMID: 36891166 Free PMC article. Review.
-
Bleeding Disorders in Women and Girls: State of the Science and CDC Collaborative Programs.J Womens Health (Larchmt). 2022 Mar;31(3):301-309. doi: 10.1089/jwh.2022.0008. J Womens Health (Larchmt). 2022. PMID: 35275742 Free PMC article. Review.
-
Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD.Blood Adv. 2021 Apr 27;5(8):2079-2086. doi: 10.1182/bloodadvances.2020004141. Blood Adv. 2021. PMID: 33877293 Free PMC article.
References
-
- Leebeek FW, Eikenboom JC. Von Willebrand’s disease. N Engl J Med. 2016;375(21):2067–2080. - PubMed
-
- Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood. 1987;69(2):454–459. - PubMed
-
- Werner EJ, Broxson EH, Tucker EL Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893–898. - PubMed
-
- Zimmerman TS, Ratnoff OD, Powell AE. Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand’s disease, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Invest. 1971;50(1): 244–254. - PMC - PubMed
-
- Sadler JE, Budde IJ, Eikenboom JC, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103–2114. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
